Physician profile

Peter Mcandrews

Orthopaedic Surgery · Traverse City, MI

NPI 1396784013

$1,734.00

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$213.82

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medwest Associates $805.00 2019
Zimmer Biomet Holdings, INC. $553.74 2019-2022
Stryker Corporation $117.86 2022
Djo, LLC $105.41 2023 Aircast, Donjoy
Bioventus LLC $55.50 2024 Exogen Ultrasound Bone Healing System, Durolane
Ferring Pharmaceuticals INC. $32.88 2023-2024 Euflexxa
Pacira Pharmaceuticals Incorporated $28.83 2022
Biocomposites INC $20.03 2024
Orthofix Medical, INC. $14.75 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Peter Mcandrews

$1,734.00

in general payments reported 2019-2025

Years
2019-2024
Top company
Medwest Associates

https://glasscript.com/doctor/18088/peter-mcandrews

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.